Gout

Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks. SUA <300 μmol/L at Week 36: 63.8% vs 40.7% (p<0.0001) A 23% difference on the most stringent urate target. Well tolerated and acceptable safety profile Abstr LB0008 @RheumNow https://t.co/PSrn7K5BVS

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR091506, an extended formulation release of Febuxostat to prolong response was superior to Febuxostat at WK36. Unclear if will proceed to regulatory submission @RheumNow https://t.co/9lcVEzcxc1

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
New Insights in Gout Clinical Management https://t.co/Eo63NUhaY2 https://t.co/oHZG1c1LhL

Links:

Dr. John Cush @RheumNow( View Tweet )
Weight management should be discussed!! Obesity management will help rheumatic diseases. EULAR guidelines below. No ACR ones exist. Best evidence in OA and Gout. #EULAR2026 plenary @RheumNow https://t.co/hBu4YeXZbu

Links:

Bella Mehta @bella_mehta( View Tweet )
ULT de-escalation in Gout: shall we do it? Short answer: No RCT 309 pts 24 mo Primary outcome remission last 6 mo 79.2% ULT continuation vs 62.9% discontinuation p=0.002 Flare incidence 12% vs 32% More NSAID/colchicine use after stopping ULT Stopping ULT = urate rises quickly & https://t.co/bYKr5axu46

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
EULAR flags

New Insights in Gout Clinical Management

EULAR – The European Alliance of Associations for Rheumatology – held its 2026 annual Congress in London, where gout was high on the agenda. Current guidelines recommend lifelong urate-lowering therapy (ULT) in a treat-to-target (T2T) strategy to maintain remission, although there

Read Article
Which of the following is NOT a complication of Gout?

Dr. John Cush @RheumNow( View Tweet )

healthcare workers

WSJ: Nurse Practitioner Is Now the Hottest Job in Healthcare

Jack Cush, MD

The Wall St. Journal has published a perspective on nurse practitioners (NP) and their very promising careers.

The U.S. healthcare system is undergoing a

Read Article
RheumNow Podcast square

Quiz Talk (5.22.2026)

Jack Cush, MD

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

Read Article
Meet the RheumNow #EULAR2026 Reporting Team Delivering real-time insights from the forefront of rheumatology: 🩺 Dr. Antoni Chan (@synovialjoints) 🩺 Dr. Mrinalini Dey (@DrMiniDey) 🩺 Dr. Jiha Lee (@JihaRheum) 🩺 Dr. Aurelie Najm (@AurelieRheumo) 🩺 Dr. Janet Pope https://t.co/zpIeGWpL6P
Dr. John Cush @RheumNow( View Tweet )
Dr. Robert Terkeltaub walks through the evolution of gout at #RheumNowLive 2026. 🎧 Listen here: https://t.co/S6RXQo2Umt #Gout #Rheumatology #MedEd https://t.co/XDbTmj3MOw

Links:

Dr. John Cush @RheumNow( View Tweet )
Gout Control Lowers Cardiovascular Events A large target emulation trial suggests that gout patients prescribed urate-lowering treatment who achieve a serum urate level lower than 6 mg/dL significantly lower their risk of cardiovascular events. https://t.co/LcBg7yCw4c https://t.co/dBYdnq9XLJ

Links:

Dr. John Cush @RheumNow( View Tweet )
CV.CP_.Heart_.pericarditis

Gout Control Lowers Cardiovascular Events

Jack Cush, MD

A large target emulation trial suggests that gout patients prescribed urate-lowering treatment who achieve a serum urate level lower than 6 mg/dL significantly lower their risk of cardiovascular events.

Cohorts were derived from the Clinical Practice Research

Read Article
lectures

Great Lectures; Great Presentations

Jack Cush, MD

Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.

Read Article
RheumNow Podcast square

Prescribing Lessons (4.17.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
Global Study of #gout - incidence increased by 158% (from 1990 to 2023), during which mean onset agerose from 58 to 62 years; but % young-onset gout dropped 15.8% to 9.8%. #s due to aging, not younger onset. https://t.co/5pqMwPEnuj https://t.co/414vJHnBYi

Links:

Dr. John Cush @RheumNow( View Tweet )
Couldn’t attend https://t.co/4UQlqwujiR 2026? You can now watch the entire meeting On Demand. This high-impact program features leading experts discussing: • RA outcomes and pathogenesis • Obesity, inflammation, and rheumatic disease • Treatment decisions in Psoriatic https://t.co/A3wb3pzbl3

Links:

Dr. John Cush @RheumNow( View Tweet )
Worldwide Trends in Hyperuricemia A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates. https://t.co/qXx2tLcj8b https://t.co/bQ861Hkcb8

Links:

Dr. John Cush @RheumNow( View Tweet )
uricacid.jpg

Worldwide Trends in Hyperuricemia

Jack Cush, MD

A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates

Read Article
Managing Gout in CKD Patients A current review article addressed the management of gout patients with chronic kidney disease (CKD). This full read review addresses the epidemiology, challenges, treatment decisions, and outcomes. https://t.co/ND0cspcmDd https://t.co/HI55D5koZj

Links:

Dr. John Cush @RheumNow( View Tweet )
Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower serum uric acid levels, by approximately 0.6 to 1.5 mg/dL. They increase renal uric acid excretion via a uricosuric effect), thereby reducing gout risk by 30% to 50%. https://t.co/weXVOhpiP9 https://t.co/NsCRNi9JI9

Links:

Dr. John Cush @RheumNow( View Tweet )
Gout pills injection

Managing Gout in CKD Patients

Jack Cush, MD

A current review article addressed the management of gout patients with chronic kidney disease (CKD).  This full read review addresses the epidemiology, challenges, treatment decisions and outcomes. 

The prevalence of gout rises with each stage of CKD; from 4%, 6% to 10%, 11%

Read Article
US Epidemiologic survey data from NHANES gout prevalence is incr. in RA pts vs controls (10.3% vs. 4.8%, P < 0.001), increasing trend over time. RA is as an independent risk factor for gout (OR: 2.67), strongest in SNRA. Evidence for the converse may not be as strong. https://t.co/hhRT9NCzVG
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

UBER Rheumatology Ride (3.6.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com

Read Article
Metanalysis of 8 articles, 2655 gout pts shows that ELEVATED neutrophil-to-lymphocyte ratio (NLR; SMD: 0.75; 95% CI: 0.48–1.03) and platelet-lymphocyte ratio (PLR; SMD: 0.52; 95% CI: 0.24–0.79) showed significant value in predicting acute gout attacks https://t.co/RaArPdoc2s https://t.co/Qi2WDSPlde

Links:

Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

Advanced Practice Rheum

Gout

Jack Cush, MD
APR video gout cover

Dr. Jack Cush reviews Gout in this continuing series for Advanced Practice Rheum.

Read Article
Advanced Practice Rheum

Evaluation of Rheumatic Complaints

Jack Cush, MD
Eval of Rheum Complaints Cover Image
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article

A Brief History of Rheumatoid Arthritis Mimics

Robert Schoen, MD, MBA
books history
Imagine that 100 years from now, your great granddaughter, an eminent rheumatologist, reviews the history of rheumatoid arthritis mimics.
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • Daily Recap Day 1 + 2 EULAR 2026
×